This device has demonstrated survival benefits that increase over time, with long-term data showing a 16.3% absolute reduction in mortality at 10 years and an average of 600 additional days alive for users.

Impella CP is the first mechanical circulatory support device proven in a randomized controlled trial to significantly improve both short-term and long-term survival for patients suffering from cardiogenic shock related to STEMI, a leading cause of in-hospital death.

Cardiogenic shock complicates up to 10% of the approximately 750,000 annual STEMI cases in the U.S., making this advancement particularly significant in reducing in-hospital mortality.

Long-term follow-up data published in the New England Journal of Medicine confirms that Impella CP provides increasing survival benefits over time, with a 16.3% absolute mortality reduction at 10 years and patients gaining an average of 600 days alive.

Johnson & Johnson emphasizes its commitment to addressing major health challenges through its cardiovascular solutions portfolio and innovative MedTech tools designed to support heart recovery, coronary artery disease, stroke, and atrial fibrillation.

The DanGer Shock trial, involving 360 patients across Denmark, Germany, and the UK from 2013 to 2018, was the first randomized controlled trial to demonstrate the survival benefits of Impella in STEMI-related cardiogenic shock, leading to its recommendation at a class 2a guideline by the American College of Cardiology and American Heart Association.

Impella, the world's smallest heart pump, is designed to temporarily support heart function by taking over the heart's pumping action, allowing the heart to rest and recover, which can potentially avoid the need for transplantation or permanent support.